ML-021
/ MapLight Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 04, 2025
Business Highlights and Upcoming Milestones
(GlobeNewswire)
- "Topline results from Phase 2 VISTA trial for ADP expected in the second half of 2027...The Company expects to complete IND-enabling studies for ML-021 in the second half of 2026."
P2 data • Preclinical • Alzheimer's Disease • Parkinson's Disease
1 to 1
Of
1
Go to page
1